AllDocs -> cancers

ELIGIBILITY FORM FLUDARABINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA AND OTHER LOW GRADE NON-HODGKIN’S LYMPHOMA AND WALDENSTROM’S MACROGLOBULINEMIA (This form should be completed before the first dose is dispensed) 1. PATIENT SURNAME 2. GIVEN NAME _ 3. DATE OF BIRTH __ __ __ __ __ __ Day Month Year 4. HEALTH INSURANCE NUMBER __ 5. CENTRE (Circle correct response) 1 Hamilton 2 Kingston 3 London 4 Ottawa Civic 5 Ottawa General 6 Sudbury 7 Thunder Bay 8 Toronto-Sunnybrook 9 Windsor 10 PMH 11 Other (specify below) Other : __ 6. ATTENDING PHYSICIAN __ If not a Cancer Centre physician, please indicate your phone number __ 7. ELIGIBILITY (Patient must meet criteria a or b) a. The patient has stage III-IV follicular or other ...

lymphoma Fellowship Grant: Application Form 2007-2009 Cover Pages (1 of 3) For LRF use only Proposal Number Receipt Date & Time Please carefully review the “Guidelines & General Instructions” before completing this Application DEADLINES: Letter of Intent must be received (electronically, as well as signed original and 3 copies) by LRF by 5:00 PM EST, July 1, 2006. Full application must be received (electronically, as well as signed original and 3 copies) by LRF by 5:00 PM EST, September 8, 2006. 1. Project Title (do not exceed more than 90 characters): 2. Name of Applicant: Degree(s): ? M.D. ? Ph.D. ? Other (specify): Title: Department: ...

Lymphoma Managing Older Patients Cheryl Tompkins RN, MSN, CRNP, AOCNP Nurse Practitioner, Stem Cell Transplant Service University of Pittsburgh Cancer Centers University of Pittsburgh Medical Center Tompkinsca@upmc.edu Page 2 Overview Classification Prognosis Treatment Focus on Follicular and Diffuse Large B-Cell NHL Special considerations for the management of the older patient with NHL Supportive Care Page 3 Non-Hodgkin’s Lymphoma Classification based on: Morphology Immunophenotype Genotype Clinical Features Page 4 Indolent and Aggressive NHL The Revised European/American Lymphoma – World Health Organization Classification (REAL/WHO) Indolent Follicular lymphoma Marginal zone B-cell ...

The Leukemia & Lymphoma Society T EAM I N T RAINING About the Society Mission The Leukemia & Lymphoma Society’s mission: Cure leukemia, lymphoma , Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. The Society has dedicated itself to being one of the top-rated vol- untary health agencies in terms of dollars that directly fund our mission. Strategic Goals • Research: To accelerate the acquisition and application of scientific understanding; to advance the treatment, diagnosis, or prevention of leukemia, lymphoma and myeloma. • Patient Services: To reach all patients at the time of diagnosis and make a significant difference in the lives of all who choose to receive the Society’s services. • Advocacy: To increase influence with private and public ...

424 JCPSP 2006, Vol. 16 (6): 424-425 I NTRODUCTION Primary non-Hodgkin’s lymphoma of the female genital tract is a rare condition, accounting for approximately 1% of primary extranodal lymphomas. 1 Freeman et al. in a review of 12447 cases of lymphoma , found only 10 cases related to the female genital tract. 2 NHL present insidiously. Majority present with painless superficial lymph adenopathy. Less commonly extranodal regions are the primary site of disease. Because of its rarity, no consensus exists on the management and treatment of primary NHL of the female genital tract. 3 Non-Hodgkin’s lymphoma usually affects older adults and, therefore, women are seldom found to have NHL when they are pregnant. C ASE HISTORY A 23 years old lady, married for the last 12 years, gravida 3 and para 2, reported ...

For research use only A224 - Lymphoma (formalin fixed) Specifications: • No. of cases: 48 • Tissue type: Lymphoma • No. of spots: 2 spots from each cancer case (96 spots) 8 non-neoplastic spots (8 spots) •Total spots: 104 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 Summary of tissue spots For research use only (formalin fixed) No Sex Age Keyword Stage 1 A 1,2 m 35 Lymph node: Hodgkin's disease ?B 2 A 3,4 f 39 Lymph node: Hodgkin's disease ?A 3 A 5,6 m 46 Lymph node: Hodgkin's disease ? 4 A ...

Data Review of aplaviroc trials Judith Millard, PhD Group Director ID Medicines Development Center, GSK Page 2 Background information • Aplaviroc development stopped due to evidence of idiosyncratic hepatoxicity • 640 subjects dosed, >350 with multiple doses in phase IIb and III • Review of SAEs, AEs and HIV associated conditions – 3 reports found • Squamous cell carcinoma • Burkitt’s Lymphoma • “Possible Lymphoma ” • None reported as “drug related” Page 3 Squamous Cell Carcinoma • 41 y female randomized to COM+APL (600mg BID) – 01APR05: vaginal discharge with blood – 18APR05: enrolled into the APL trial – 28APR05: invasive epidernoid carcinoma of vagina diagnosed by biopsy – 17MAY05: hospitalized: ...

TYPE OF CANCER: Indolent Non-Hodgkin’s Lymphoma TYPE OF TRIAL: Phase III TRIAL SPONSOR: Cephalon PRINCIPAL INVESTIGATOR: Nam Dang M.D. CONTACT PERSON: Carol Varela (702) 822-5449 STUDY SUMMARY A Multi-Center, Phase III Study to Investigate the Safety & Efficacy of TREANDA (Bendamustine HCI) in Patients With Indolent Non-Hodgkin’s Lymphoma Who Are Refractory to Rituximab TREATMENT OVERVIEW • There are 21 days in each cycle • There is a maximum of 8 cycles • Patients need to be seen by the physician at least every 21 days PRE-TREATMENT ASSESSMENTS • WHO Performance Status • ECG • LDH • Serum ß-HcG • Bone Marrow Biopsy • Disease Assessment Page 2 ENTRANCE CRITERIA FOR PARTICIPATION IN TRIAL INCLUSION CRITERIA • Documented relapsed indolent B-cell ...

TYPE OF CANCER: Diffuse Large B-Cell Lymphoma TYPE OF TRIAL: Phase II TRIAL SPONSOR: Cell Therapeutics PRINCIPAL INVESTIGATOR: Nam Dang M.D. CONTACT PERSON: Carol Varela (702) 822-5449 STUDY SUMMARY A Phase II, Randomized, Multi-Center, Comparative Trail with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophophamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Elderly Patients with Diffuse Large B-Cell Lymophoma TREATMENT OVERVIEW • Each cycle is 21 days • There is a total of 8 cycles • Patient should be seen by the physician at least every 2-3 weeks. PRE-TREATMENT ASSESSMENTS • Lymph Node Biopsy and/or CT Guided Biopsy • Bone Marrow aspirate and biopsy • Lumbar puncture • MUGA • ECG • Serum cardiac Troponin T • CT/MRI of Chest/Abdomen/Pelvis ...

190 Renal Lymphoma Case Report International Braz J Urol Vol. 32 (2): 190-192, March - April, 2006 Renal Lymphoma . Atypical Presentation of a Renal Tumor Francualdo Barreto, Marcos F. Dall’Oglio, Miguel Srougi Department of Urology, Federal University of Sao Paulo (UNIFESP), Paulista School of Medicine, Sao Paulo, Brazil ABSTRACT Primary renal lymphoma is a rare lesion that represents less than 1% of the kidney’s lesions. The authors discuss the case of a 67-year-old woman with a renal mass identified 7 years after treatment of a non-Hodgkin’s lymphoma , and analyze clinical and prognostic aspects of renal lymphomas. Radiological findings in this case showed an uncommon presentation of the renal lymphomatous lesion which served as a warning that tumors might appear during follow-up as atypical and uncommon lesions. Key words : kidney neoplasms; nephrectomy; ...

> Croat Med J. 2006;47:515-9 Book Reviews Book Reviews Field of medicine: Molecular medicine. Format:Hardcoverbook. Audience: Biomedical research- ers, pharmacologists, pathologists, oncologists, hematologists, pedi- atricians, and other clinicians re- quiringregularscientificupdates. Purpose: To give information on current molecular methods and protocols used in the understand- ing, diagnosis, classification, and therapyoflymphoma. Content: The book consists of sixteen chapters, each beginning with a summary followed by a list of key words and the main text composed of introduction, ma- terials, methods, and final notes with references. The first chap- ter deals with apoptosis and Bcl- 2 family of proteins. After a short introduction, two protocols are described. The first protocol de- scribes the isolation ...

This article was printed from the Leukemia Research Foundation website, www.leukemia-research.org Leukemia Research Foundation 820 Davis Street, Suite #420 Evanston, IL 60201 847-424-0600 Page 1 of 2 Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years 19 May 2004 Patients with leukemia or lymphoma who undergo hematopoietic-cell transplantation (HCT) and survive can expect full recovery to take 3-5 years, according to a study published in the May 19 issue of The Journal of the American Medical Association (JAMA). Hematopoietic-cell transplantation (bone-marrow transplant or stem-cells transplant) is an effective and widely used treatment for hematologic (blood) malignancies. Yet, the rate and predictors of physical and emotional recovery after HCT have not been adequately defined in long-term studies. Improved understanding ...

Patient Access Network Foundation PO Box 221858 Charlotte, NC 28222-1858 1.866.316.PANF (7263) www.patientaccessnetwork.org SUPPORTING THE NEEDS OF THE UNDERINSURED CUTANEOUS T-CELL LYMPHOMA CUTANEOUS T-CELL LYMPHOMA Cutaneous T-cell lymphoma (CTCL) is a general term for many lymphomas of the skin and can include mycosis fungoides (the most common type of CTCL), Sézary syndrome, lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma , adult T-cell leukemia/ lymphoma , peripheral T-cell lymphoma , lymphomatoid granulomatosis, granulomatous slack skin disease, and pagetoid reticulosis to name a few. Generally, CTCL is a low-grade lym- phoma which primarily affects the skin. Over time, in about 10% of the cases, CTCL can progress to the lymph nodes and internal organs. In severe cases, the malignant mature T-cells circulate in the blood stream ...

SUPPORTING THE NEEDS OF THE UNDERINSURED Patient Access Network Foundation PO Box 221858 Charlotte, NC 28222-1858 1.866.316.PANF (7263) www.patientaccessnetwork.org NON-HODGKIN’S LYMPHOMA Non-Hodgkin’s lymphoma (NHL) is a malignant growth of B or T cells in the lymph system. In the US, childhood Non-Hodgkin's lymphomas make up about 5 percent of the cases of NHL diagnosed each year. There are approximately 29 adult non-Hodgkin's lymphomas. There are several treatments for NHL. Usually chemotherapy is used. If the lymphoma is localized, radiation therapy might be used possibly in conjunction with chemotherapy. In some types of advanced NHL (but not all) bone marrow or peripheral blood stem cell transplants can be used (often for serious/ unresponsive cases). Private insurance and Medicare are the most common types of health coverage ...

137 Colon and Rectum Summary Male Female Utah 1996-2000 US 1996-99 Utah 1996-2000 US 1996-99 Average annual age-adjusted incidence rates* 23.4 23.5 14.3 15.9 Rank among cancer incidence rates 6 5 7 6 Average annual number of new cases 163 27,580 117 23,690 Percent of all new cancer cases 5.0 % 4.3 % 4.1 % 3.8 % * Rates per 100,000 and standardized to the 2000 U.S. population Lifetime risk this of cancer (00-79 years) 1 in 44 1 in 44 1 in 68 1 in 62 Average annual age-adjusted mortality rates* 10.5 10.8 7.1 7.2 Rank among cancer mortality rates 4 5 5 6 Average annual number of deaths 68 12,047 58 11,115 Percent of all cancer deaths 5.7 % 4.3 % ...

111 Broadway, New York, NY 100006, Tel: 212-349-2910, Fax: 212-349-2886, E-mail: researchgrants@ lymphoma .org 2007-09 2-YEAR POSTDOCTORAL FELLOWSHIP FOR LYMPHOMA POLICY STATEMENT AND TERMS AND CONDITIONS GOVERNING FELLOWSHIPS D EFINITIONS : Applicant: Individual who requests funding for a lymphoma research project must have completed two years of a fellowship, or not more than two years as a junior faculty instructor or assistant professor at the start of the award period ,and hold a M.D., Ph.D., or equivalent degree. LRF Fellow : Individual who is associated with a sponsoring institution and whose research project has been approved for funding by LRF. LRF Grant: Grant given by LRF to a LRF Fellow to provide funding for Hodgkin’s and/or non- Hodgkin’s lymphoma research. Sponsor: Individual associated ...

- 1 - Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response Stefano Monti 1 * , Kerry J. Savage 2 * , Jeffery L. Kutok 3 , Friedrich Feuerhake 2 , Paul Kurtin 4 , Martin Mihm 5 , Bingyan Wu 6 , Laura Pasqualucci 7 , Donna Neuberg 6 , Ricardo C.T. Aguiar 2 , Paola Dal Cin 3 , Christine Ladd 1 , Geraldine S. Pinkus 3 , Gilles Salles 8 , Nancy Lee Harris 6 , Riccardo Dalla-Favera 7 , Thomas M. Habermann 9 , Jon C. Aster 3 , Todd R. Golub 1,10** , Margaret A. Shipp 2** 1 The ...

Non-Hodgkin's lymphoma is the commonest lymphoma seen in people with HIV. A lymphoma is the name given to a tumour (or growth) of lymphocytes (white blood cells). Non- Hodgkin's lymphoma (NHL) is caused by the unregulated production of B-cells, and is sometimes called B-cell lymphoma . B-cells are one of the two main classes of lymphocytes, (the other being the T-cells).They are produced in the bone marrow and spleen and are involved in the production of antibodies. In HIV infection, B-cells typically become ‘over- active'. People who are infected with Epstein-Barr virus (which also causes glandular fever), may develop a generalised increase in B-cell reproduction. In some people, particularly if the immune system is suppressed, the continuous replication of B-cells may cause lymphoma . NHL may occur in the lymph nodes (glands), spleen, digestive system, liver, kidney or – in a particular ...

Facts About Lymphoma Page 2 All organs are made up of cells. • Normally, cells grow and die in an orderly way. • If a cell turns into a cancer, the cell multiples and accumulates. This growth causes tumors to form. In lymphoma , cancer develops in the lymphatic system. The lymphatic system: • is the part of the immune system – the body’s defense against infection • runs throughout the whole body. Normal Cells Cancerous Cells Lymphoma is a type of cancer This booklet is designed to provide information in regard to the subject matter covered. It is distributed by The Leukemia & Lymphoma Society with the understanding the Society is not engaged in rendering medical or other professional services. Page 3 -2- ...

Mantle Cell Lymphoma No. 4 in a series providing the latest information on blood cancers. Lymphoma , a type of cancer that begins in a lymphocyte, is divided into two major categories: Hodgkin lymphoma and all other lymphoma (also referred to as non-Hodgkin Lymphoma .) Additional information about lymphoma appears in The Leukemia & Lymphoma Society booklet, The Lymphomas . This fact sheet provides specific information about mantle cell lymphoma , a type of non-Hodgkin lymphoma . It includes information about diagnosis, treatment, expected outcomes and additional resources. What are the roles of lymphocytes and the lymphatic system? A lymphocyte is a type of white blood cell. Lymphocytes compose about 20 percent of the white cells in the blood. Most lymphocytes are found in the lymph nodes (small bean- shaped structures located throughout the body) and other organs of the lymphatic ...

Radioimmunotherapy as a Treatment for Lymphoma No. 18 in a series providing the latest information on blood cancers. Radioimmunotherapy is a newly approved cancer treatment that combines two types of therapies — radiation therapy and immune therapy using monoclonal antibodies . Monoclonal antibodies are immune proteins made in the laboratory to target and attach to a special part (an antigen ) of the surface of a cell. Radiation-emitting molecules, referred to as radioisotopes , can be attached to the monoclonal antibodies. Those monoclonal antibodies targeted to cancer cells can carry the radiation-emitting molecule to the cancer cells, resulting in more localized, target-specific irradiation. Once attached to the surface of the cancer cell, the radioisotope may kill the cancer cells. Some normal cells that share the same antigen might also be killed. Radioimmunotherapy is being studied in several cancers, ...

Cutaneous T Cell Lymphoma No. 5 in a series providing the latest information on blood cancers. Lymphoma is a type of cancer that begins in a lymphocyte. This disease is divided into two major categories: Hodgkin lymphoma and all other lymphomas (also referred to as non- Hodgkin Lymphoma .) Additional information about lymphomas appears in The Leukemia & Lymphoma Society booklet, The Lymphomas . This fact sheet provides specific information about cutaneous (skin) lymphoma , a relatively uncommon type of non-Hodgkin lymphoma . It includes information about diagnosis, treatment, expected outcomes and additional resources. What are the roles of lymphocytes and the lymphatic system? A lymphocyte is a type of white blood cell. Lymphocytes compose about 20 percent of the white cells in the blood. Most lymphocytes are found in the lymphatic system, the major part of the body’s immune system. The ...

Lymphoma www.catie.ca What is lymphoma ? Lymphoma is a cancer of the lymphatic system of the body. The lymphatic system of the body includes lymphatic vessels, lymph nodes, tonsils, the spleen and the thymus. These organs and tissues contain a type of white blood cell called lymphocytes. There are two types of lymphocytes—T cells and B cells. Both are responsible for fighting diseases and infections in the body. Lymphoma is usually caused by abnormal production and growth of the B lymphocytes. How does lymphoma affect people with HIV/AIDS? There are two main types of lymphomas: Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (NHL). NHL is the most common type of lymphoma seen in people with HIV/AIDS. In people with HIV/AIDS, lymphoma is linked to immune deficiency. When the immune system becomes weak, the B lymphoctyes in the body may become overactive and grow at an abnormal ...

Review Article Pyothorax-associated Lymphoma Katsuyuki Aozasa In Japan, EBV positive rate in immunocompetent patients with nodal lymphomas is less than 10%in B-cell and 20 - 50%in T cell lymphoma . Among extranodal lymphomas, EBV positive rate is higher in pyothorax-associated lymphoma (PAL), nasal NK/T-cell lymphoma , and adrenal lymphoma . PAL is non-Hodgkin’s lymphoma that develops from chronic pyothorax resulted from artificial pneumothorax for the treatment of lung tuberculosis or tuberculous pleuritis. This disease was originally described by Dr. Aozasa as a distinctive clinicopathologic entity in 1987, and now listed as the disease entity in the WHO classification of Tumours, Pathology & Genetics, Tumours of the Lung, Pleura, Thymus and Heart (2004). INTRODUCTION In 1987, Aozasa and colleagues reported three patients with pleural lymphoma , which developed after long-standing ...

26 AIDS-Related Lymphoma (ARL) Igor Melnychuk, MD Fellow, Division of Infectious Disease and Tropical Medicine University of South Florida, Tampa Manuel Guerra, MD Senior Attending Physician, Division of Hematology/Oncology Department of Medicine, Mercy Hospital, Miami Epidemiology • In 1984, Non-Hodgkin’s Lymphoma (NHL) was described as one of the diseases with increased incidence/risk in the AIDS population • AIDS-related lymphoma (ARL) represents the second most frequent cancer associated with AIDS after Kaposi’s sarcoma • Lymphoma is a late manifestation of HIV disease – Serves as an initial AIDS-defining condition in almost 16% of patients – Majority of patients have relatively low CD4+ cell counts (less than 200 cells/mm3) • ARL is more common in men than in women • All age groups are affected, and lymphoma is the most common malignancy in HIV-infected ...

•hcsp FACT sheet• Hepatitis C Support Project • www.hcvadvocate.org a series of fact sheets written by experts in the field of liver disease Extrahepatic Manifestations: Non-Hodgkin’s Lymphoma (NHL) NHL iN peopLe witH Hepatitis C is uNCommoN . In addition, most studies show that the incidence of NHL in people with hepatitis C usually occurs after many years of infection with hepatitis C. The designation “Non-Hodgkin’s Lymphomas” encompasses a variety of cancers of white blood cells that affect the lymphoid tissues. The exact cause of these cancers is not fully understood but it is believed to be caused by an altered or depressed immune system. Other conditions and medication have been linked to NHL include HIV infection, immunosuppressive medications, rheumatic diseases and hepatitis C. The lymphatic system is a circulatory system ...

The incidence of lymphomas has increased steadily for both men (29% increase) and women (45% increase) over the last 20 years. The level of mortality for men and women has increased only slightly during that time. Background notes Lymphoma (Hodgkins & Non-Hodgkins Lymphomas combined) Page 2 Male Lymphoma - Incidence and Mortality* 1977-2000 All Ages Includes Hodgkins and Non-Hodgkins Lymphomas Source - SA Cancer Registry 0 5 10 15 20 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 Year *Age Standardised for World Population R a t e / 1 0 0 0 0 0 Incidence Mortality Male Lymphoma Incidence and Mortality* 1977-2000 ...

Delivery of drugs to the target sites by the use of carrier systems has recently been the major area of drug delivery research. Incorporation of drugs into delivery carriers prevents drugs from degradation, targets the drug to the site of action and reduces toxi- city or side effects by modifying their in vivo distribution (1). Delivery of anticancer ag- ents using carrier systems with an objective of enhancing their tumor concentrations has been widely attempted (2–5). Over the years, surfactants have been of pharmaceutical interest either as drug carriers or, more recently, as targeting systems. From the toxico- logical point of view, non-ionic surfactants are generally regarded as safe and most suit- 143 Acta Pharm. 56 (2006) 143–155 Original research paper Enhanced delivery of etoposide to Dalton’s lymphoma in mice through polysorbate 20 micelles LAKKIREDDY HARIVARDHAN REDDY ...

Lymphoma DIAGNOSIS Hematopatholo- Excisional lymph node H&P exam Bone marrow biospy and aspirate CBC, Diff, Plt, Na, k ,T Prot, Alb, BUN creatinine, calcium, phosphorous, LDH, SGPT, alkaline phosphatase, total bilirubin, glucose, uric acid HIV If anemic at presentation: Coombs and Haptoglobin CRX PA & Lateral CRX CT Scans : - Abdomen / pelvis -Head and Neck( if head and neck presentation) -Endoscopy, upper GI, barium enema (if gastrointestinal symptoms present or GI disease suspected) Skeletal films( if bone pain present-Bone Scan) PATHOLOGICAL DIAGNOSIS (Page 1 of 4) biopsy gy consult Tissue handling required Follow Hemato pahology Guidelines for Lymphomas Echocardiogram -Chest if CXR abnormal Hodgkin's Disease Hodgkin's Disease Stages ...

Lymphoma Foundation of America 814 N. Garfield Street $ Arlington, VA 22201 REFERRAL LIST Lymphoma Specialists NORTHEAST George Canellos, M.D. (800) 320-0022 (617) 632-3470 Lee Nadler, M.D. (800) 320-0022 (617) 632-3331 Arnold Freedman, M.D. (800) 320-0022 (617) 632-3441 Dana-Farber Cancer Institute Boston, MA Vincent DeVita, M.D. (203) 785-4370 Yale Cancer Center New Haven, CT Carol Portlock, M.D. (800) 525-2225 (212) 639-8109 Memorial Sloan-Kettering Cancer Center New York, NY Morton Coleman, M.D. (212) 517-5900 Richard Silver, M.D. (212) 746-2098 New York Hospital/Cornell Medical Center New York, NY Richard Fisher, M.D. (585) 275-5823 James P. Wilmot Cancer Center Rochester, NY John Glick, M.D. (800) 789-PENN (215) 662- 6334 University of Pennsylvania ...